welcome to NeuroVice

No more spoons, towels, or pencils. No more pain. No more blood. No more suffering without a solution. FINALLY, MEET PATI, A SEIZURE SOLUTION FOR ORAL HEALTH.

0 MILLION
PEOPLE WITH EPILEPSY IN U.S.
0
ARE CHILDREN
0 MILLION
65 million worldwide have epilepsy

We have finally developed a solution.

Meet PATI, The Protector Against Tongue Injury, developed by a patient for a patient. 

PATI is the first, symptom-management, oral device technology that safely and effectively prevents tongue biting and oral trauma during seizures. 

PATI’s patent-pending, disposable design prevents dislocation or dislodgement during the episode, allows for natural airflow, and prevents saliva from collecting in the mouth which can lead to choking. 

0 MILLION
people live with seizures caused by strokes, traumatic brain injuries, brain tumors, multiple sclerosis and cerebral palsy

NeuroVice is on a mission to disrupt the current safety guidelines by giving seizure sufferers a safe and effective, first-to-market, solution - PATI.

IT'S EASY TO GET STARTED

  • GET A PRESCRIPTION FROM YOUR DOCTOR
  • VISIT PHARMACY
  • GET YOUR PATI KIT

The PATI Kit comes with a set of PATIs, a portable container, and a wristband. When you run out of PATIs, simply refill your prescription.

Ashlyn Sanders, CEO & Founder

In 2014, Ashlyn was diagnosed with a rare and life-threatening neurologic condition called a Chiari Malformation, that led to emergent brain surgery and causes seizures. There is no cure for Chiari Malformations. Ashlyn started the company based on her desire to improve the patient experience for millions of others living with seizures.  

Ashlyn is a graduate of UNC-Chapel Hill (B.A. Mathematics) and Duke University (M.A. Bioethics and Science Policy). She is also a former 2014 Spring White House Intern during the Obama Administration in The Office of Science and Technology Policy and The Office of Public Engagement. She is passionate about health and health policy and is very active in her community. After getting PATI to market, Ashlyn plans to attend medical school to pursue Neuropsychiatry.